Documentation of pediatric drug safety in manufacturers' product monographs: A cross-sectional evaluation of the Canadian Compendium of Pharmaceuticals and Specialities

Pediatric Drugs

Volumn 10, Issue 3, 2008, Pages 193-197

  Uppa, Navjeet K ^a   Dupuis, Lee L ^a,b,c   Parshuram, Christopher S ^a,b,d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Children; Formularies; Pharmacovigilance

Indexed keywords

ARTICLE; CANADA; DOCUMENTATION; DRUG FORMULARY; DRUG INDICATION; DRUG INDUSTRY; DRUG SAFETY; EVALUATION; HUMAN; INFANT; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; CANADA; CHEMISTRY, PHARMACEUTICAL; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DOCUMENTATION; DRUG INDUSTRY; DRUG INTERACTIONS; DRUG THERAPY; FORMULARIES, HOSPITAL; GUIDELINES AS TOPIC; HOSPITALS, PEDIATRIC; HUMANS; INFANT; INFANT, NEWBORN; PEDIATRICS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PRESCRIPTIONS, DRUG; PUBLISHING;

EID: 43049107542     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200810030-00007     Document Type: Article

References (25)

1. Gilman JT, Gal P. Pharmacokinetic and pharmacodynamic data collection in children and neonates: a quiet frontier. Clin Pharmacokinet 1992 Jul; 23 (1): 1-9
2. Hill P. Off license and off label prescribing in children: litigation fears for physicians. Arch Dis Child 2005 Feb; 90 Suppl.: i17-8
3. Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf 2006 Sep; 5 (5): 703-18
4. Blumer JL. Off-label uses of drugs in children. Pediatrics 1999; 104 (3 Pt 2): 598-602
5. McLay JS, Tanaka M, Ekins-Daukes S, et al. A prospective questionnaire assessment of attitudes and experiences of off label prescribing among hospital based paediatricians. Arch Dis Child 2006 Jul; 91 (7): 584-7
6. Wong I, Sweis D, Cope J, et al. Paediatric medicines research in the UK: how to move forward? Drug Saf 2003; 26 (8): 529-37
7. Conroy S, McIntyre J. The use of unlicensed and off-label medicines in the neonate. Semin Fetal Neonatal Med 2005; 10: 115-22
8. Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications for safety. Drug Saf 2002; 25 (1): 1-5
9. Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr 2005; 164 (9): 552-8
10. Repchinsky C, editor. Compendium of Pharmaceuticals and Specialities. The Canadian Drug Reference for Health Professionals 2005 ed. Ottawa (ON): Canadian Pharmacists Association, 2005
11. Branch HP. Drug monographs 2007 [online]. Available from URL: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/monograph/ pm_mp_ e.html [Accessed 2007 Dec 19]
12. Sung L, Simons JA, Dayneka NL. Dilution of intravenous N-acetylcysteine as a cause of hyponatremia. Pediatrics 1997; 100 (3 Pt 1): 389-91
13. Brubacher J, Purssell R, Kent D. Salty broth for salicylate poisoning? Adequacy of overdose management advice in the 2001 Compendium of Pharmaceuticals and Specialties. Can Med Assoc J 2002 Oct 29; 167 (9): 992-6
14. Electronic Canadian compendium of pharmaceuticals and specialities [online]. Available from URL: http://www.e-cps.ca [Accessed 2005 Aug 1]
15. Kowalczyk A, editor. The 2004-2005 formulary of drugs. 23rd ed. Toronto (ON): Hospital for Sick Children, 2004
16. Impicciatore P, Choonara I, Clarkson A, et al. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001 Jul; 52 (1): 77-83
17. Weinstein MC. The cost-effectiveness of orphan drugs. Am J Public Health 1991 Apr; 81 (4): 414-5
18. Wilson JT, Kearns GL, Murphy D, et al. Paediatric labelling requirements: implications for pharmacokinetic studies. Clin Pharmacokinet 1994; 26 (4): 308-25
19. Koren G. Healthy children as subjects in pharmaceutical research. Theor Med Bioeth 2003; 24 (2): 149-59
20. Kearns GL. Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J Allergy Clin Immunol 2000 Sep; 106 (3 Suppl.): S128-38
21. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology: drug disposition, action and therapy in infants and children. N Engl J Med 2003; 349 (12): 1157-67
22. Giacoia GP, Birenbaum DL, Sachs HC, et al. The newborn drug development initiative. Pediatrics 2006 Mar; 117 (3 Pt 2): S1-8
23. Cuatrecasas P. Drug discovery in jeopardy. J Clin Invest 2006; 116 (11): 2837-42.
24. Roberts R, Rodriguez W, Murphy D, et al. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA 2003; 290 (7): 905-11
25. Pasquali SK, Sanders SP, Li JS. Oral antihypertensive trial design and analysis under the pediatric exclusivity provision. Am Heart 2002 Oct; 144 (4): 608-14